United States - English - NLM (National Library of Medicine)

maryhelene enterprises inc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a) - topical analgesic for the temporary relief of pain. condition worsens or if symptoms persist for more than 7 days or clear up and occur again within a few days.

United States - English - NLM (National Library of Medicine)

maryhelene enterprises inc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a) - topical analgesic for the temporary relief of pain. condition worsens or if symptoms persist for more than 7 days or clear up and occur again within a few days.

Philippines - English - FDA (Food And Drug Administration)

marklene fabricate corp - capsaicin, menthol, methyl salicylate, gengerol - rub - 15mg+250mg/g

Philippines - English - FDA (Food And Drug Administration)

marklene fabricate corp - capsaicin,menthol, methyl salicylate,gengerol - liniment - 4.5mg+4mg+250mg+15mg/g

Philippines - English - FDA (Food And Drug Administration)

marklene fabricate corp - capsaicin,menthol,methyl salicylate,gengerol - liniment - 15mg+80mg+250mg

Philippines - English - FDA (Food And Drug Administration)

marklene fabricate corp - quassinoids - shampoo - 30mg/ml

Philippines - English - FDA (Food And Drug Administration)

marklene fabricate corp - quassinoids - shampoo - 30mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott medical australia pty ltd - 35852 - defibrillator, implantable, automatic - the unify assura cd3361-40c is a cardiac resynchronisation therapy device with rf telemetry and it monitors and regulates the patient?s heart rate by providing ventricular tachyarrhythmia therapy and single site pacing. it features an is-1/df-1 device header and parylene coating. the unify assura cd3361-40c is intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias. cardiac resynchronization therapy devices (crt-ds) are also intended to resynchronize the right and left ventricles in patients with congestive heart failure. also at/af detection algorithm is indicated for detecting atrial tachyarrhythmias which have been found to be associated with an increased risk of stroke in elderly, hypertensive, pacemaker patients without prior history of af.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott medical australia pty ltd - 35852 - defibrillator, implantable, automatic - the unify assura cd3361-40qc is a cardiac resynchronisation therapy device with rf telemetry and it monitors and regulates the patient?s heart rate by providing ventricular tachyarrhythmia therapy and single site pacing. it features a df4 device header and parylene coating. the unify assura cd3361-40qc is intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias. cardiac resynchronization therapy devices (crt-ds) are also intended to resynchronize the right and left ventricles in patients with congestive heart failure. also at/af detection algorithm is indicated for detecting atrial tachyarrhythmias which have been found to be associated with an increased risk of stroke in elderly, hypertensive, pacemaker patients without prior history of af.

United States - English - NLM (National Library of Medicine)

maryhelen oriental medicine research - levomenthol (unii: bz1r15mtk7) (levomenthol - unii:bz1r15mtk7), methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz) - levomenthol 0.09 g - external analgesic uses  for the relief of pain in breasts. do not use: • on wounds • on infected or damaged skin • while exercising or performing sweaty activities (yoga, swimming, and etc.,) when using this product: • avoid contact with eyes or mouth • do not bandage tightly stop use and ask a doctor if: • condition worsens • symptom clear up and occur again within a few days. • symptom persist for more than 7 days. • nausea, vomiting, abdominal discomfort, diarrhea, or skin rash occurs. • excessive irritation of the skin develops